For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230928:nRSb0117Oa&default-theme=true
RNS Number : 0117O Bank of America Merrill Lynch 28 September 2023
FORM 38.5(a)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED
INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader: Merrill Lynch International
Company dealt in HORIZON THERAPEUTICS PLC
Class of relevant security to which the Common - IE00BQPVQZ61
dealings being disclosed relate(Note 1)
Date of dealing 27/09/2023
Merrill Lynch International
Company dealt in
HORIZON THERAPEUTICS PLC
Class of relevant security to which the
dealings being disclosed relate(Note 1)
Common - IE00BQPVQZ61
Date of dealing
27/09/2023
2. DEALINGS (Note 2)
(a) Purchases and sales
Total number of relevant securities acquired Highest price paid (Note 3) Lowest price paid (Note 3)
Total number of securities disposed Highest price received (Note 3) Lowest price received (Note 3)
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD
(Note 4) (Note 5)
(Note 3)
Swaps Increasing a Long Position 389 115.7 USD
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 5) Exercise price Type, e.g. American, European etc Expiry date Option money paid/ received per unit (Note 3)
N/A N/A N/A N/A N/A N/A N/A
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option
unit (Note 3)
N/A N/A N/A
3. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights
or future acquisition or disposal of any relevant securities to which any
derivative
referred to on this form is referenced. If none, this should be stated.
Rehypothecation of 4,224 shares
Loan of 58 shares
Date of disclosure 28/09/2023
Contact name Frank Lui
Telephone number +44207 996 6418
Name of offeree/offerer with AMGEN INC
which connected
Nature of connection(Note 6) Advisor to - AMGEN INC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ITPPPUGWBUPWUBR